Pell Bio Med Technology Co Ltd
TWSE:6949
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fastighetsbolaget Emilshus AB
STO:EMIL PREF
|
SE |
Pell Bio Med Technology Co Ltd
Research & Development
Pell Bio Med Technology Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pell Bio Med Technology Co Ltd
TWSE:6949
|
Research & Development
-NT$265.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GenMont Biotech Inc
TWSE:3164
|
Research & Development
-NT$45.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
Adimmune Corp
TWSE:4142
|
Research & Development
-NT$266.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
|
|
E
|
Energenesis Biomedical Co Ltd
TWSE:6657
|
Research & Development
-NT$194.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Kim Forest Enterprise Co Ltd
TWSE:6645
|
Research & Development
-NT$27.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Pell Bio Med Technology Co Ltd
Glance View
Pell Bio-Med Technology Co., Ltd. operates as a biotechnology company. The company is headquartered in Taipei City, Taipei. The company went IPO on 2024-03-08. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The firm is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
See Also
What is Pell Bio Med Technology Co Ltd's Research & Development?
Research & Development
-265.9m
TWD
Based on the financial report for Dec 31, 2024, Pell Bio Med Technology Co Ltd's Research & Development amounts to -265.9m TWD.
What is Pell Bio Med Technology Co Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
-25%
Over the last year, the Research & Development growth was -11%. The average annual Research & Development growth rates for Pell Bio Med Technology Co Ltd have been -25% over the past three years .
